For LEAD Model ACOs · PY1 2027–2036
ChorusRx embeds precision pharmacy inside your care model — clinical pharmacists, pharmacogenomic testing and medication-safety analytics that find the drug interactions driving your avoidable admissions, ED visits and falls. Under LEAD, every admission you prevent in 2027 keeps paying you back until 2036.
Implementation period runs September 15 – December 31, 2026.1
Emergency department visits a year in the U.S. for adverse drug events; almost 500,000 require hospitalization.2
Fewer inpatient days, and 6.8% fewer ED visits, in a peer-reviewed study of a pharmacogenomics-enriched medication management program in retired public-sector Medicare members.12
Higher odds of hospital admission for older adults with polypharmacy; 2.5× for ED visits.3
Medication-related hospitalizations judged potentially preventable through systematic regimen review.4
The opportunity
Under the Global Risk Option you hold up to 100% of savings and up to 100% of losses. Under Professional, up to 60% of savings and up to 50% of losses.1 Either way, your result is decided by avoidable utilization in a population of older adults with multiple chronic conditions — and the single most modifiable driver of that utilization is what is in their medication list.
Medication-related harm is not spread evenly across your panel. It clusters in the frail, dual-eligible, 10-plus-medication cohort — the same beneficiaries who set your benchmark performance and your quality scores. A ranked risk list turns a population problem into a work list of a few hundred people.
Most population-health levers — screening rates, diet, behavioral change — take years to show in claims. Deprescribing a duplicate anticholinergic, resequencing a sedative to bedtime, or catching a post-discharge discrepancy changes risk this month. In year one of a ten-year model, speed is worth more than elegance.
LEAD holds your historical baseline for the full ten years with trend updates and no mid-model rebasing.1 The savings you generate in 2027 are not competed away by your own improved performance in 2030. That is a materially different investment case than the Shared Savings Program.
Why the ten-year lock changes the math
In a rebased model, this year's savings become next cycle's target. In LEAD, they don't. That single design choice converts medication optimization from an annual cost-avoidance exercise into a compounding asset on your balance sheet.
It also raises the cost of waiting. A cohort you leave un-reviewed through PY1 is not a one-year miss — it is a gap you carry against a fixed baseline for the remainder of the model. ACOs that front-load medication work in the implementation period start PY1 with a cleaner population and a lower run rate against a benchmark set before the cleanup.
Illustrative schematic of benchmark mechanics, not a projection of results. It shows the structural difference between a baseline held for the model period and one that resets — it is not a forecast for any specific ACO.
Quality crosswalk
LEAD withholds 3% of the benchmark against quality performance — money you must earn back rather than upside you might win.1, 5 The measure set carries the ACO REACH backbone forward: four claims-based measures — all-condition readmission, unplanned admissions, days at home and post-acute follow-up — the CAHPS patient experience survey, and two eCQMs with optional reporting in PY2027–2028.6 Here is where a medication intervention actually lands.
| LEAD measure | Type | The medication mechanism | What ChorusRx does about it |
|---|---|---|---|
| All-cause unplanned admissions for older adults with multiple chronic conditions | Claims | Adverse drug events are among the most preventable admission triggers in precisely this cohort. Anticoagulants alone account for roughly 21% of ADE-related ED visits, diabetes agents 14%.2 | Whole-regimen risk scoring across the aligned population, then pharmacist-led intervention on the highest-risk decile — multi-drug competition, duplicate therapy, and dose-appropriateness for renal and hepatic function. |
| Risk-standardized all-condition readmission | Claims | Unreconciled discharge medication changes and high-risk classes — anticoagulants, opioids, insulin, diuretics — are leading, well-documented drivers of 30-day readmission. | Discharge medication reconciliation, high-risk-class monitoring through the post-acute window, and pharmacist follow-up timed to land before the readmission clock runs out. |
| Days at home for patients with complex, chronic conditions | Claims | Cumulative sedative and anticholinergic burden drives falls; falls drive fracture, hospitalization and SNF days. Days at home is lost one fall at a time. | Cumulative burden scoring, time-of-administration resequencing so sedating agents land at bedtime, targeted deprescribing, and Precision Compliance Packaging to keep the regimen executable at home. |
| Timely follow-up after acute exacerbations of chronic conditions | Claims | The transition out of the hospital is where regimens quietly break: unreconciled discharge changes, duplicate classes, and the medications nobody stopped. Re-exacerbation follows. | Admission-first and discharge reconciliation, on-demand pharmacist access for the care team during the follow-up window, and a closed loop back to the prescriber. |
| Patient experience (CAHPS) | Survey | Patients rate care through how they feel and how hard their day is. Side-effect burden, dosing complexity and pharmacy friction sit underneath the items about getting needed care and provider communication. | Fewer medications taken more simply; packaging organized by time of day; direct pharmacist counseling so patients and families understand what changed and why. |
| Blood pressure control | eCQM | Apparent non-response is often pharmacokinetic or adherence-driven rather than a dosing problem — multiple agents competing for the same metabolic pathway, or a regimen the patient cannot execute. | Interaction- and pharmacogenomic-informed agent selection, competition analysis across the full regimen, and simplification to sustain adherence. |
| Diabetes: glycemic status > 9% | eCQM | Insulin and sulfonylureas are consistently among the leading causes of ADE-related emergency visits.2 Both over- and under-treatment show up here, and both are regimen-design problems. | Hypoglycemia risk flagging, regimen simplification, and goal-of-care alignment for frail beneficiaries where tight control is the harm rather than the target. |
| Continuous improvement & High Performers Pool | Bonus | Earning improvement credit and pool eligibility requires a lever that visibly moves year over year — not one that plateaus after the easy gains. | Monthly cohort refresh against each new alignment file, so every performance year opens with a fresh ranked work list rather than last year's. |
| Prevention Quality Plan | Bonus | ACOs can earn additional quality points by submitting a Prevention Quality Plan describing a prevention intervention for aligned beneficiaries.6 Falls and medication-driven harm reduction are exactly the kind of intervention this is built to score. | Our medication-safety and falls-prevention program is submission-ready as your Prevention Quality Plan from month one — a second lever on quality points beyond the core measure set. |
Scroll the table horizontally on smaller screens. Measure specifications are set by CMS guidance; confirm current definitions in the LEAD measurement methodology.6
The differentiator
ChorusRx puts pharmacogenomic testing inside the medication management process — not beside it. PGx results feed directly into regimen decisions rather than sitting in a report nobody acts on. It is the difference between a population-level warning and a patient-level answer.
Illustrative: a flagged medication cleared once genotype shows the patient metabolizes it normally — one false-positive interaction the pharmacist doesn't have to chase down.
Two patients on identical regimens do not carry identical risk. A poor metabolizer on a standard dose is over-exposed; an ultra-rapid metabolizer is under-treated and looks like non-adherence. Neither shows up in an interaction check, and both drive the utilization LEAD measures.
Just as valuable in a risk-bearing model: genotype clears combinations that a rules-based system flags. That is fewer false-positive interventions, less prescriber alert fatigue, and clinical pharmacist capacity spent on the patients who will actually benefit.
A genotype does not change. In LEAD's ten-year performance period with stable attribution, a single test keeps informing every prescribing decision for that beneficiary across the entire model — an unusually good match between a one-time cost and a decade-long accountability horizon.
A test result doesn't rewrite a prescription by itself. Our Clinical Pharmacists work the finding into the regimen under collaborative practice, direct with the prescriber. That's the step a diagnostics or genetic-counseling vendor hands back to you to finish.
We offer performance guarantees on the program, underwritten to your population. A testing or counseling vendor sells you a service fee; on a benchmark you carry for ten years, a partner willing to put its own fee on the line is a different kind of decision.
Option A · Our core model
ChorusRx delivers PGx-enriched comprehensive medication management end to end: risk stratification across your aligned population, testing for the cohorts where it changes decisions, Clinical Pharmacist review under collaborative practice, prescriber collaboration, and Precision Compliance Packaging where adherence is the binding constraint — with performance guarantees and measure-level reporting built in from month one.
For ACOs with no in-house clinical pharmacy — which LEAD was explicitly designed to attract.1 This is where we compete hardest, and where our model is structurally hardest to substitute with a test-and-report vendor.
Option B · If you already have a program
Already have an MTM vendor, a health-plan program, or your own clinical pharmacists? Keep them. ChorusRx supplies pharmacogenomic testing, interpretation and decision support that flows into their process — no rip-and-replace, no vendor consolidation fight.
Testing is targeted rather than universal. We stratify first and test where genotype is likely to change a prescribing decision — which keeps the economics defensible in a total-cost-of-care model instead of asking you to fund a population-wide panel.
Why ChorusRx
Accountable care organizations are who we build for. We are not a generic medication therapy management vendor adapting to risk — the model we bring you was designed for total-cost-of-care accountability from the start.
Everything on this page is aimed at one buyer: an ACO accountable for the total cost and quality of a complex Medicare population. The model behind it was proven in the most demanding version of that problem — full-risk capitated programs for frail, dually eligible, multi-chronic older adults, including PACE — where a preventable admission has nowhere to hide. You are not getting a pilot. You are getting a program that has already had to work when someone else was carrying the risk.
ChorusRx offers value-based partnering agreements with performance guarantees and shares financial risk when outcomes are not achieved. Guarantees are underwritten to your population and negotiated case by case, once we have seen enough of your data to commit honestly. An ACO carrying up to 100% downside should not be the only party at the table with something to lose — and a vendor selling a test or a report has nothing on the line.
Pharmacogenomic testing is core to how our Clinical Pharmacists work, not an add-on report. Genotype tells you which patient cannot metabolize the drug they were prescribed, and which flagged interactions are safe to ignore. Layered on top: whole-regimen analysis of multi-drug, drug–disease and drug–gene interactions, plus sedative and anticholinergic burden, fall risk and QT prolongation — not the pairwise checks your EHR already does.
We instrument the program against the LEAD claims measures — readmission, unplanned admissions, days at home, timely follow-up — and report at measure level, not activity level. You should be able to see what the 3% withhold is doing, monthly.
Primary Care Capitation, Enhanced PCC, Total Care Capitation and the new Non-Primary Care Capitation give LEAD ACOs prospective dollars to deploy against total cost of care.1 That means clinical pharmacy can be funded from the payment you already receive — no waiting on a billing code, a MAC coverage determination, or provider-status reform.
The published weakness of medication review programs is not the analysis — it is uptake. Recommendations arrive as a PDF and die there. Our Clinical Pharmacists work under collaborative practice inside your care team, alongside your physicians and nurses, closing the loop with the prescriber rather than notifying them.
LEAD was deliberately designed to bring in smaller, independent and rural practices and organizations serving underserved populations1 — the organizations least likely to have in-house clinical pharmacy. We are that layer, delivered remotely, without you hiring a pharmacy department.
LEAD lowers alignment minimums for ACOs where more than 40% of beneficiaries meet high-needs criteria, and applies separate risk adjustment and benchmarking to that population.7 Dual-eligible, homebound and post-acute beneficiaries are exactly the cohort our model was built around and proven on.
Honest comparison
Most ACOs already have something in this space. The question is whether it moves claims.
| Capability | EHR interaction alerts | Annual consultant review | PBM / plan MTM program | ChorusRx |
|---|---|---|---|---|
| Evaluates the entire regimen simultaneously | No — pairwise only | Varies by reviewer | Usually rules-based | Yes |
| Drug–gene and drug–disease interactions | No | Rarely | Limited | Yes |
| Pharmacogenomic testing and expert interpretation built into the review | No | Rarely | Typically a separate benefit, if covered at all | Yes — core to the process |
| Can layer onto the medication program you already have | N/A | Replaces or duplicates | Competes with it | Yes — genetic intelligence layer |
| Cumulative sedative / anticholinergic and fall-risk burden | No | Sometimes | No | Yes |
| Pharmacist embedded in the care team workflow | No | Point-in-time | Telephonic, outside your team | Yes, under collaborative practice |
| Reported against LEAD claims measures | No | No | Reports plan metrics | Yes, at measure level |
| Fundable from LEAD capitation without new billing pathways | Bundled in EHR cost | Fee-based | Plan-controlled | Yes |
| Vendor shares financial risk on outcomes | No | No | No | Performance guarantees |
| Standing up before PY1 opens | Already live, not working | Scheduling-limited | Outside ACO control | Weeks, from claims and alignment data |
Model your upside
Move the sliders to your ACO. This is a transparent, assumption-driven estimate designed to frame a conversation — not a guarantee, and not a substitute for actuarial modeling on your own claims. Every assumption is listed underneath.
LEAD requires 5,000 aligned beneficiaries for standard ACOs, 800 for high-needs ACOs, and 1,000 for organizations newly entering accountable care.7
Above 40%, LEAD applies separate risk adjustment, benchmarking and trend to this population.7
Pull this straight from your own claims or utilization reporting — your ACO's all-cause acute admission rate, not an estimate we're asking you to guess.
The honest variable, and the one nobody can know in advance. Reviews that end in a report capture very little; embedded pharmacists with prescriber authority capture more. Start conservative.
Global participants receive up to 100% of savings and bear up to 100% of losses; Professional participants receive up to 60% of savings and bear up to 50% of losses.1
See "Two ways to engage" above. Option A is ChorusRx's embedded Clinical Pharmacists running medication management end to end — the model the studies below describe. Option B plugs pharmacogenomic testing into a medication management program you already run, and is modeled conservatively at roughly a third of Option A's effect, since none of the cited studies isolate a testing-only pathway.
Estimated retained savings, year one
— per member per month across the aligned population
Assumptions. Admission volume for the standard population is computed
directly from the admission rate you enter, not a fixed figure. Blended benchmark of
$1,150 PBPM for standard and $3,300 PBPM for high-needs beneficiaries; roughly 8% of
standard-population acute admissions treated as medication-related, consistent with
published estimates4; of those, two-thirds treated as potentially
preventable4; $19,000 average Medicare cost per avoided acute
admission16; two ED visits avoided per admission avoided at $1,300
each. High-needs beneficiaries are modeled instead on the $218.34 PMPM medical cost
savings published for a PGx-enriched medication management program in a Medicare
population closely matched to LEAD high-needs criteria12, not the
standard-population admission math — both figures scale with the capture rate and
engagement option above. Ten-year figure is the year-one retained amount held flat across
the model period and is not discounted — it illustrates the effect of a benchmark that is
not rebased, not a projection of results. Change any of these in
assets/app.js. Not a guarantee of savings.
How it runs
We do not need a year of integration work before producing anything useful. Risk stratification runs off claims and alignment data you already receive, which means the first ranked work list can exist before Performance Year 1 opens.
Now – December 31, 2026 · Implementation period1
Data use agreement, alignment file and claims review, and whole-regimen risk scoring across your population. You end the implementation period holding a ranked medication-risk cohort and a named intervention plan for the top decile — plus the target list for pharmacogenomic testing, sequenced by where genotype is most likely to change a prescribing decision.
Q1 2027 · PY1 opens
Genetic sample collection for the target cohort, Clinical Pharmacist reviews informed by those results, prescriber collaboration under collaborative practice agreements, deprescribing and resequencing, and Precision Compliance Packaging deployed where adherence is the binding constraint.
Q2 – Q4 2027
Monthly cohort refresh as voluntary alignment updates arrive, expansion beyond the first decile, on-demand pharmacist support for post-acute transitions, and measure-level reporting against unplanned admissions, days at home and timely follow-up.
2028 – 2036
Each performance year opens with a fresh ranked list against a benchmark that does not rebase. Add Part D premium buy-down strategy as it becomes available in 20291 and extend into CARA episode arrangements — including CARA's own episode-based falls prevention program, a direct fit for a model already built around sedative and anticholinergic burden.1
Evidence
You're taking on up to 100% downside risk for ten years under LEAD. The clinical approach behind ChorusRx has been tested by outside researchers — in Medicare, PACE and self-insured populations — and it holds up.
PACE case study · Quasi-experimental, HCC risk-adjusted · 19 organizations
Across 19 PACE organizations, 2018–2019: participants receiving structured medication risk mitigation services saw total costs grow $4,386 per participant year-over-year, versus $9,410 for those without — a $5,024 difference, driven mostly by facility costs (hospital, ED, skilled nursing).15 Research conducted by CareKinesis/Tabula Rasa Healthcare, our founder Calvin H. Knowlton's prior company.
Lower year-over-year cost growth per participant (p<0.001)
Of the savings came from facility costs alone
Add pharmacogenomics to that same medication review, and two independent, peer-reviewed studies — different research teams, different populations — show the effect compounds.
Study 1 · Medicare population · Difference-in-differences
Teachers' Retirement System of the State of Kentucky. 5,288 members who completed genetic testing and pharmacist consultations compared against 22,357 eligible members who did not enrol, over 32 months. Participants averaged 73.7 years of age, 13.0 medications and a Charlson Comorbidity Index of 3.6 — a population that closely resembles a LEAD high-needs cohort.12
Fewer inpatient days — 141.03 fewer per 1,000 members/yr
Fewer emergency department visits
PMPM medical cost savings; ~$37M cumulative
Had actionable genetic findings against a current medication
Study 2 · Self-insured employer population · Propensity-matched cohort
452 participants in a self-insured employer's pharmacogenomics-enriched medication management program, compared against 1,500 propensity-matched controls over 26 months.13
Fewer inpatient visits (p=0.05)
Fewer ED visits (p=0.002)
PBPM lower inpatient cost (p=0.04)
In an analysis of drug claims for 213,561 Medicare beneficiaries with one year of follow-up, each one-point increase in a validated medication risk score was associated with more adverse drug events, more hospitalizations, more emergency department visits, higher Part A and B costs, and greater mortality. Odds of a fall were 2.28×, 3.47× and 5.43× higher across intermediate, high and severe risk tiers versus minimal.8
In 1,965 Program of All-Inclusive Care for the Elderly (PACE) participants, each one-point increase in a validated medication risk score corresponded to 8.6% higher odds of an adverse drug event, roughly $1,037 in additional annual medical spending, and more ED visits and hospitalizations per 100 participants — the dually eligible, multi-chronic cohort that most closely resembles a LEAD high-needs population.9 A companion pharmacogenomics study in the same PACE population found 146 genetic variants, 169 drug-gene interactions and 125 drug-drug-gene interactions per 100 participants tested — evidence for why testing this population, specifically, is worth doing.14
More than 1.5 million ED visits a year in the U.S. are for adverse drug events, with almost 500,000 requiring hospitalization. Adults 65 and over account for more than 600,000 of those visits — more than twice the rate of younger people.2 Anticoagulants, diabetes agents and antibiotics lead the causes.2
Systematic reviews of pharmacist-led deprescribing consistently show improved medication appropriateness and reduced inappropriate prescribing — one review found a mean reduction of 1.74 medications with intensive strategies — but effects on hospitalization and mortality remain heterogeneous, with authors attributing the gap to low uptake of pharmacist recommendations and short follow-up.10 That finding is the reason our model is embedded and prescriber-integrated rather than advisory, and the reason we accept performance guarantees. It is also why you should ask us for measure-level reporting from month one.
High Needs ACOs led the way with a 14% net savings rate in ACO REACH Performance Year 2024 — evidence that the sickest, most complex Medicare populations are where accountable care economics work hardest. ACO REACH PY2024 financial and quality results. Of 115 participating ACOs covering 2.5 million beneficiaries, 96 earned shared savings and 19 recorded losses.11
ChorusRx offers performance guarantees that share financial risk if outcomes are not achieved, structured around the return the program actually generates for your population. We will walk you through the underlying client data under NDA — including the cases where it took longer than we projected — and put specific commitments in writing once we have both seen the same numbers.
This isn't borrowed science. Our founder, Calvin H. Knowlton, co-authored the PACE medication-risk and pharmacogenomics research cited above — the same peer-reviewed studies in notes 9 and 14 — and has spent his career building medication-safety programs for exactly this population.
Questions LEAD ACOs ask
No. Risk stratification runs off claims and alignment data you already receive — not an EHR integration project. A data use agreement and a claims extract are enough to produce a ranked medication-risk cohort, which is the only deliverable you strictly need before January 1. Deeper workflow integration can follow during PY1 without delaying the first intervention wave.
It's the right question to ask — this is the classic shared-savings "ratchet": if you lower utilization during your benchmark's base years, you lower your own benchmark, and the improvement gets absorbed rather than paid out. That's exactly why our implementation-period work is scoped to data agreements, claims review and risk stratification — analysis that touches zero claims — while actual clinical intervention (deprescribing, testing, dose changes, prescriber collaboration) is sequenced to begin in Q1 2027, after your base-year window closes. Planning now costs you nothing on the benchmark; it just means PY1 opens with a ranked work list already in hand instead of a blank page. One nuance if you're a Renewing ACO: CMS's Prior Savings Adjustment gives a positive benchmark credit for savings you already generated in ACO REACH or the Shared Savings Program in the three years before LEAD — so a track record you're already building under an existing arrangement carries forward rather than working against you.
You do not need one. LEAD pays participants prospectively through Primary Care Capitation, Enhanced PCC, Total Care Capitation and the new Non-Primary Care Capitation, plus the Advanced Payment Option. Those are ACO dollars you may deploy against total cost of care. Most engagements are structured as a per-member-per-month fee funded from capitation, a shared-savings arrangement, or a hybrid with performance guarantees attached.
ChorusRx contracts with your ACO as a vendor and service partner. We are not a LEAD model participant, we do not hold attributed beneficiaries, and we do not bill Medicare for the ACO's aligned population — so we do not implicate the model's participant-overlap restrictions. Confirm the specifics of your own arrangement with counsel; we will support that review with whatever documentation your compliance team needs.
To start: the alignment file and Part A/B/D claims, under a data use agreement consistent with your CMS obligations. Optional but valuable: an EHR feed or medication list export for the highest-risk cohort. You receive a ranked risk cohort, per-patient intervention recommendations routed to the prescriber, and measure-level reporting mapped to the LEAD claims measures rather than activity counts.
Then take the genetic intelligence layer rather than the full program. Your existing pharmacists and MTM workflows stay exactly as they are; ChorusRx supplies pharmacogenomic testing, expert interpretation and decision support that flows into their process. The medication management you already fund starts making better-informed decisions on the same patients, and you avoid a vendor consolidation fight. If your existing program is telephonic and disconnected from the care team, we will say so and make the case for more — but the layered model is a genuine option, not a fallback.
No — universal panel testing is hard to defend economically in a total-cost-of-care model, and we do not propose it. We stratify the aligned population first and test where genotype is likely to change a prescribing decision: high medication counts, implicated drug classes, and beneficiaries already showing signs of non-response or intolerance. Testing is then funded through the commercial arrangement, from LEAD capitation, or billed where coverage exists — we will model the options against your specific population before you commit. A genotype is a one-time cost that stays useful for the life of the beneficiary's attribution, which is unusually favourable over a ten-year model.
Not unless you want us to. The clinical program — risk analytics, pharmacist review, prescriber collaboration — works alongside whatever dispensing arrangements your beneficiaries already use. Where fulfillment is itself the failure point, we can provide comprehensive pharmacy management including Precision Compliance Packaging organized by time of administration.
Better, and substantially. Medication risk concentrates in frail, multi-morbid, high-polypharmacy beneficiaries, so the same intervention produces more avoided events per patient reviewed. These are also the beneficiaries our model was built around and proven on, across full-risk capitated programs, long-term care, skilled nursing and home-based care.
Intervention volume and medication-risk reduction are visible within the first 60 to 90 days. Claims-based utilization measures lag by the claims runout itself, so plan on two to three quarters before unplanned admissions and days at home move detectably. We report leading indicators monthly so you are not waiting on settlement data to know whether the program is working.
Yes. We offer value-based partnering agreements with performance guarantees and share financial risk where outcomes are not achieved. We will discuss specific guarantee structures once we have seen enough of your population data to underwrite them honestly — we would rather scope a guarantee we can meet than sign one we cannot.
Next step
A working session with a ChorusRx Clinical Pharmacist and our LEAD lead — not a capabilities deck. Bring your alignment estimate and your risk option, and we will map medication risk against the measures that decide your withhold.
We reply within one business day.
The published outcomes in notes 8, 12 and 13 describe programs and analytics operated by other organizations, cited as evidence for the clinical approach. Notes 9, 14 and 15 come from research conducted at CareKinesis/Tabula Rasa Healthcare, our founder Calvin H. Knowlton's prior company, in the same PACE population ChorusRx serves today. Nothing on this page is a guarantee of savings or of performance under the LEAD Model. Model rules are set by CMS and may change; verify all model parameters against current CMS guidance.
